MorphoSys Hopes FDA Incentive Programs Can Boost Proprietary Plans
This article was originally published in The Pink Sheet Daily
MorphoSys’s ambition to grow a proprietary pipeline got a boost with FDA giving its lead compound MOR208 fast track status for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
You may also be interested in...
MorphoSys is putting on a brave face after Celgene handed back rights to its anti-CD38 monoclonal antibody MOR202, saying it will carry on with current trials in multiple myeloma patients and voicing confidence it can find another commercial partner “once the time is right.”
Flush with funds from new partnering deals and recent capital injections, German biotech MorphoSys plans to boost its already considerable R&D spending to build value in the pipeline while holding on to promising assets longer.
After searching a year and a half for the right compound to complete its proprietary pipeline, German MorphoSys completed a biotech-biotech deal with a simpatico California company.